Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04022343 | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | active not recruiting | Phase 2 | 22 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | active not recruiting | Phase 3 | 747 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 5, 2026 | clinicaltrials |
| NCT04620603 | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | active not recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06056505 | Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy(3DPN) | completed | N/A | 370 | University of LeipzigOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07557563 | Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04659343 | TDM for Optimized Outcome in Patients With mRCC. | recruiting | — | 200 | Niels FristrupOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer | terminated | N/A | 106 | Roswell Park Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02121730 | Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions(FRISC) | completed | — | 2,500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03354390 | HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 1 | 17 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05023265 | Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT(AQuOS-II) | recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07504939 | Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | — | 36 | Peking University First HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01590069 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | active not recruiting | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06138496 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04393350 | Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 18 | Emory UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540260 | CAIX PET/ CT Guided Radiation Therapy in CcRCC.(COSTAR-002) | recruiting | N/A | 70 | Peking University First HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT00814021 | Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain | completed | Phase 2 | 21 | Institut Claudius RegaudOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00918775 | Follow-up After Metastasectomy in Patients With Kidney Cancer | active not recruiting | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03575611 | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma | suspended | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03810651 | Pencil Beam Scanning in Patients With Renal Tumors | recruiting | Early Phase 1 | 28 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04028245 | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma(SPARC-1) | completed | Early Phase 1 | 17 | Columbia UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04693377 | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04953104 | ARID1A and/or KDM6A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05347212 | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | terminated | Phase 1 | 1 | Instil BioINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03846128 | Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer(BIOSUNTOX) | terminated | — | 6 | University Hospital, RouenOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06525831 | Rein 3D PRINT MECHANICS(Rein3DP-M) | recruiting | N/A | 50 | University Hospital, BordeauxOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07117227 | Validation of RCC Predicting Model With Emulated-target Trial(RCCETT) | recruiting | — | 4,700 | Peking University Third HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT04416646 | Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma(ZEBRA) | completed | — | 100 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05210933 | Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry(SMART) | suspended | — | 750 | University of AlbertaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05969496 | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus(NEOPAX) | recruiting | Phase 2 | 17 | University of Colorado, DenverOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02087852 | Kidney Cancer DNA Registry | recruiting | — | 750 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06020651 | Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside(VICKI) | completed | N/A | 39 | Institut Mutualiste MontsourisOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT07402109 | CBCT Guided Markerless SBRT for Renal Cell Cancer(CT-STARRS) | recruiting | N/A | 40 | Erasmus Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2026source: clinicaltrials